October 2022 "Systolic heart failure (HF) is a chronic clinical syndrome characterized by the reduction in cardiac function and still remains the disease with the highest mortality worldwide. Despite considerable advances in pharmacological treatment, HF represents a severe clinical and social burden. Chronic human HF is characterized by several important neurohormonal perturbations, emanating from both the autonomic nervous system and the adrenal glands. Circulating catecholamines (norepinephrine and epinephrine) and aldosterone elevations are among the salient alterations that confer significant hormonal burden on the already compromised function of the failing heart. This is why sympatholytic treatments (such as β-blockers) and renin-angiotensin system inhibitors or mineralocorticoid receptor antagonists, which block the effects of angiotensin II (AngII) and aldosterone on the failing heart, are part of the mainstay HF pharmacotherapy presently. The adrenal gland plays an important role in the modulation of cardiac neurohormonal stress because it is the source of almost all aldosterone, of all epinephrine, and of a significant amount of norepinephrine reaching the failing myocardium from the blood circulation. Synthesis and release of these hormones in the adrenals is tightly regulated by adrenal G protein-coupled receptors (GPCRs), such as adrenergic receptors and AngII receptors. In this review, we discuss important aspects of adrenal GPCR signaling and regulation, as they pertain to modulation of cardiac function in the context of chronic HF, by focusing on the 2 best studied adrenal GPCR types in that context, adrenergic receptors and AngII receptors (AT 1 Rs). Particular emphasis is given to findings from the past decade and a half that highlight the emerging roles of the GPCR-kinases and the β-arrestins in the adrenals, 2 protein families that regulate the signaling and functioning of GPCRs in all tissues, including the myocardium and the adrenal gland." Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs Interestingly, RGS (Regulators of G protein signaling) proteins, which negatively regulate GPCR signaling, have been ; (d) RGS20 was found to be significantly associated with some tumor-related signaling pathways and long

December 2021 OMass Therapeutics 's founder, Carol Robinson , has been awarded the prestigious Louis-Jeantet Chemistry from The Franklin Institute " Huge congratulations to our founder, Carol Robinson , who has been Her work in the field has been instrumental and is set to shape the future of drug discovery for years

The presence and impact of CXCR4-LPA1 heteromers on CXCL12-induced signaling and cell migration have been Authors Jong Min Hong , Jin-Woo Lee , Dong-Seung Seen , Jae-Yeon Jeong , Won-Ki Huh Tags Cancer , Chemokine

Zhang , Jiawei Zhou , Jianqiang Guo , Yafeng Liu , Chao Liang , Wenyang Wang , Yingru Xing , Jing Wu , Dong

, 2023 Abstract "Odorant receptors, traditionally associated with olfaction as chemoreceptors, have been amine-associated receptors (TAARs), formyl peptide receptors (FPRs), and membrane-spanning 4A family (MS4As) has been Authors Sung Jin Park , Paul L Greer , Namgyu Lee Source Contribute to the GPCR News Coming soon Become